Changes in mucosal status, microcirculation parameters, and immunological parameters in response to combined non-hormonal therapy for vulvovaginal atrophy: A prospective study
- Authors: Motovilova T.M.1,2, Sirotina L.Z.1,2, Martiantseva I.V.2, Trifonova O.I.2, Kruglova I.A.3, Kazakova K.V.1, Varnavskaya A.D.1, Kosareva V.A.1
-
Affiliations:
- Privolzhsky Research Medical University
- Clinic of Modern Technologies “Sadko”
- City Clinical Hospital No. 35
- Issue: Vol 27, No 4 (2025)
- Pages: 330-338
- Section: ORIGINAL ARTICLE
- URL: https://ogarev-online.ru/2079-5831/article/view/373732
- DOI: https://doi.org/10.26442/20795696.2025.4.203484
- ID: 373732
Cite item
Full Text
Abstract
Background. The relevance of age-related diseases stems from the ongoing aging of the population; in Russia, the share of women over 45 is 57.3%. The typical presentation of age-related changes includes vulvovaginal atrophy (VVA), which has extensive symptoms. The intimate nature of the problem often prevents women from discussing it openly. Hormone therapy is a traditional treatment option for VVA and its symptoms; however, it has some limitations.
Aim. To compare the clinical effect of a combination therapy with hyaluronic acid and a phytoestrogen complex, as well as antimicrobial peptides and cytokines, with traditional local hormonal therapy.
Materials and methods. The study included 68 female patients with VVA symptoms and 72 females without VVA manifestations. VVA patients were divided into two groups: in the test group, women received combined trophic therapy, and in the control group, subjects received traditional local hormone therapy. To assess the effectiveness of treatment at baseline and at 1 and 3 months after the end of therapy, analyses of cytological tests, ultrasound examinations, and enzyme immunoassays were performed, and a vaginal health index was calculated.
Results. The overall treatment effectiveness in the test group was not inferior to that of local hormone therapy, as indicated by laboratory and instrumental parameters. Two therapeutic approaches had different effects on immunological parameters: in the test group, the level of interleukin-6 in vaginal swabs of patients receiving a combination of a protein-peptide complex, cytokines, hyaluronic acid, and phytoestrogens significantly decreased and differed significantly from that in the comparison group.
Conclusion. The described non-hormonal approach to the treatment of VVA manifestations has significantly fewer limitations for use than hormonal agents, a pronounced positive effect on local immunity, and is well tolerated by patients. Therefore, the combination of hyaluronic acid and a phytoestrogen complex, as well as antimicrobial peptides and cytokines, is effective and safe and can become an alternative to traditional hormonal treatment.
About the authors
Tatiana M. Motovilova
Privolzhsky Research Medical University; Clinic of Modern Technologies “Sadko”
Author for correspondence.
Email: tmshka@mail.ru
ORCID iD: 0000-0002-3795-2852
D. Sci. (Med.)
Russian Federation, Nizhny Novgorod; Nizhny NovgorodLiya Z. Sirotina
Privolzhsky Research Medical University; Clinic of Modern Technologies “Sadko”
Email: tmshka@mail.ru
ORCID iD: 0000-0001-5081-1053
Assistant
Russian Federation, Nizhny Novgorod; Nizhny NovgorodIrina V. Martiantseva
Clinic of Modern Technologies “Sadko”
Email: tmshka@mail.ru
ORCID iD: 0000-0003-4909-5250
Laboratory Head
Russian Federation, Nizhny NovgorodOksana I. Trifonova
Clinic of Modern Technologies “Sadko”
Email: tmshka@mail.ru
ORCID iD: 0009-0005-6976-429X
Ultrasound Diagnostic Doctor
Russian Federation, Nizhny NovgorodIrina A. Kruglova
City Clinical Hospital No. 35
Email: tmshka@mail.ru
ORCID iD: 0000-0001-7955-349X
Clinical Laboratory Diagnostics Physician
Russian Federation, Nizhny NovgorodKseniia V. Kazakova
Privolzhsky Research Medical University
Email: tmshka@mail.ru
ORCID iD: 0009-0002-1849-5817
Medical Resident
Russian Federation, Nizhny NovgorodAnastasiya D. Varnavskaya
Privolzhsky Research Medical University
Email: tmshka@mail.ru
ORCID iD: 0009-0009-8767-4414
Medical Resident
Russian Federation, Nizhny NovgorodVarvara A. Kosareva
Privolzhsky Research Medical University
Email: tmshka@mail.ru
ORCID iD: 0009-0007-8695-1008
Student
Russian Federation, Nizhny NovgorodReferences
- Carlson K, Nguyen H. Genitourinary syndrome of menopause. StatPearls. Treasure Island (FL): StatPearls Publishing, 2025.
- Nappi RE, Seracchioli R, Salvatore S, et al. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study. Gynecol Endocrinol. 2019;35(5):453-9. doi: 10.1080/09513590.2018.1563883
- Portman DJ, Gass MLS; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-8. doi: 10.1097/GME.0000000000000329
- Оразов М.Р., Силантьева Е.С., Радзинский В.Е., и др. Факторы риска развития и механизмы патогенеза генитоуринарного менопаузального синдрома. Российский вестник акушера-гинеколога. 2023;23(4):44-9 [Orazov MR, Silantyeva ES, Radzinskii VE, et al. Risk factors and pathogenetic mechanisms of genitourinary menopausal syndrome. Russ Bull Obstet Gynecol. 2023;23(4):44-9 (in Russian)]. doi: 10.21508/1027-4065-2023-23-4-44-49
- Зиганшина Л.З., Муслимова С.Ю., Сахаутдинова И.В., Зулкарнеева Э.М. Симптомы и клиника постменопаузальной вульвовагинальной атрофии в различные стадии постменопаузы. Гинекология. 2023;25(2):153-7 [Ziganshina LZ, Muslimova SY, Sakhautdinova IV, Zulkarneeva EM. Symptoms and clinic of postmenopausal vulvovaginal atrophy in different stages of postmenopause: A cross sectional study. Gynecology. 2023;25(2):153-7 (in Russian)]. doi: 10.26442/20795696.2023.2.202132
- Andreeva EN, Sheremetyeva EV. The role of estriol in the treatment of atrophy of the mucous membrane of the lower genitourinary tract in postmenopausal women. Probl Endokrinol (Mosk). 2022;68(6):157-63. doi: 10.14341/probl13198
- Nappi RE, Cucinella L, Martini E, Cassani C. The role of hormone therapy in urogenital health after menopause. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101595. doi: 10.1016/j.beem.2021.101595
- Villa P, Cipolla C, D'Ippolito S, et al. The interplay between immune system and microbiota in gynecological diseases: a narrative review. Eur Rev Med Pharmacol Sci. 2020;24(10):5676-90. doi: 10.26355/eurrev_202005_21359
- Rodriguez-Garcia M, Patel MV, Shen Z, Wira CR. The impact of aging on innate and adaptive immunity in the human female genital tract. Aging Cell. 2021;20(5):e13361. doi: 10.1111/acel.13361
- Madanchi H, Shoushtari M, Kashani HH, Sardari S. Antimicrobial peptides of the vaginal innate immunity and their role in the fight against sexually transmitted diseases. New Microbes New Infect. 2019;34:100627. doi: 10.1016/j.nmni.2019.100627
- Byrne EH, Song H, Srinivasan S, et al. Association between vaginal microbiota and vaginal inflammatory immune markers in postmenopausal women. Menopause. 2024;31(7):575-81. doi: 10.1097/GME.0000000000002362
- Довлетханова Э.Р. Диагностика ВПЧ-ассоциированных заболеваний шейки матки у женщин в постменопаузе. Проблемы и пути решения. Фарматека. 2022;29(6):71-5. [Dovletkhanova ER. Diagnosis of HPV-associated cervical diseases in postmenopausal women. Problems and solutions. Farmateka. 2022;29(6):71-5 (in Russian)]. doi: 10.18565/pharmateca.2022.6.71-75
- Jais M, Younes N, Chapman S, et al. Reduced levels of genital tract immune biomarkers in postmenopausal women: implications for HIV acquisition. Am J Obstet Gynecol. 2016;215(3):324.e1-324.e10. doi: 10.1016/j.ajog.2016.03.041
- Оразов М.Р., Демяшкин Г.А., Токтар Л.Р. Ремоделирующая лазерная терапия влагалища при генитоуринарном менопаузальном синдроме. Хирургическая практика. 2018;(1):22-37 [Orazov MR, Demyashkin GA, Toktar LR. Remodeling laser therapy of the vagina in genitourinary menopausal syndrome. Surg Pract. 2018;(1):22-37 (in Russian)]. doi: 10.17238/issn2223-2427.2018.1.22-37
- Оразов М.Р., Силантьева Е.С., Радзинский В.Е., и др. Эффективность лазерной ремоделирующей терапии при генитоуринарном менопаузальном синдроме. Гинекология. 2022;24(6):465-70 [Orazov MR, Silantyeva ES, Radzinsky VE, et al. Efficacy of laser remodeling in the genitourinary syndrome of menopause: A review. Gynecology. 2022;24(6):465-70 (in Russian)]. doi: 10.26442/20795696.2022.6.201897
- Stephens P, Genever P. Non-epithelial oral mucosal progenitor cell populations. Oral Dis. 2007;13(1):1-10. doi: 10.1111/j.1601-0825.2006.01314.x
- Parsonage G, Filer AD, Haworth O, et al. A stromal address code defined by fibroblasts. Trends Immunol. 2005;26(3):150-6. doi: 10.1016/j.it.2004.11.014
- Agrawal S, LaPier Z, Nagpal S, et al. A randomized, pilot trial comparing vaginal hyaluronic acid to vaginal estrogen for the treatment of genitourinary syndrome of menopause. Menopause. 2024;31(9):750-5. doi: 10.1097/GME.0000000000002390
- Менопауза и климактерическое состояние у женщины. Клинические рекомендации Министерства здравоохранения Российской Федерации. 2025. Режим доступа: https://cr.minzdrav.gov.ru/preview-cr/117_3. Ссылка активна на 14.03.2025 [Menopauza i klimaktericheskoe sostoianie u zhenshchiny. Klinicheskie rekomendatsii Ministerstva zdravookhraneniia Rossiiskoi Federatsii. 2025. Available at: https://cr.minzdrav.gov.ru/preview-cr/117_3. Accessed: 14.03.2025 (in Russian)].
- Мотовилова Т.Б., Сиротина Л.З., Трифонова О.Ю., и др. Негормональные терапевтические возможности при вульвовагинальной атрофии. Разбор клинических случаев. Гинекология. 2025;27(1):87-91 [Motovilova TB, Sirotina LZ, Trifonova OI, et al. Non-hormonal therapies for vulvovaginal atrophy: Clinical cases. Gynecology. 2025;27(1):87-91 (in Russian)]. doi: 10.26442/20795696.2025.1.203132
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины [117_2]. 2024. Режим доступа: https://cr.minzdrav.gov.ru/archive. Ссылка активна на 20.08.2024 [Ministerstvo zdravookhraneniia Rossiiskoi Federatsii. Klinicheskie rekomendatsii. Menopauza i klimaktericheskoe sostoianie u zhenshchiny [117_2]. 2024. Available at: https://cr.minzdrav.gov.ru/archive. Accessed: 20.08.2024 (in Russian)].
- Peker H, Gursoy A. Relationship between genitourinary syndrome of menopause and 3D high-frequency endovaginal ultrasound measurement of vaginal wall thickness. J Sex Med. 2021;18(7):1230-5. doi: 10.1016/j.jsxm.2021.05.004
- Warinsiriruk P, Tantitham C, Cherdshewasart W, et al. Effects of Pueraria mirifica on vaginal artery vascularization in postmenopausal women with genitourinary syndrome of menopause. Maturitas. 2022;161:4-10. doi: 10.1016/j.maturitas.2022.01.005
- Sirotina LZ, Potapov AL, Loginova MM, et al. Criteria for vaginal atrophic changes in genitourinary syndrome of menopause using optical coherence tomography. Sovremennye tehnologii v medicine. 2025;17(2):24-33. doi: 10.17691/stm2025.17.2.03
- Miao Y, Sudol NT, Li Y, et al. Optical coherence tomography evaluation of vaginal epithelial thickness during CO2 laser treatment: a pilot study. J Biophotonics. 2022;15(11):e202200052. doi: 10.1002/jbio.202200052
- Isaza PG. Use of growth factors for vulvo/vaginal bio-stimulation. Surg Technol Int. 2019;34:269-73.
- Galli V, Golia D'Auge T, DI Pierro F, et al. Safety and efficacy of a class II medical device based on highly purified and standardized plant extracts in the management of post-menopausal patients with vulvar and vaginal atrophy: a single-center prospective observational study. Minerva Obstet Gynecol. 2024;76(4):343-52. doi: 10.23736/S2724-606X.23.05409-X
- Sanchez-Prieto M, Mendoza N, Chedraui P, et al. An open, single center, clinical investigation to evaluate the efficacy and safety of a non-hormonal vaginal moisturizer for the symptomatic treatment of vulvovaginal atrophy in postmenopausal woman. Gynecol Endocrinol. 2025;41(1):2500480. doi: 10.1080/09513590.2025.2500480
- Мальцева Л.И., Гафарова Е.А. Альтернативная терапия симптомов генитоуринарного менопаузального синдрома у женщин. Вопросы практической кольпоскопии. Генитальные инфекции. 2023;(1):24-30 [Maltseva LI, Gafarova EA. Alternative therapy of symptoms of genitourinary menopausal syndrome in women. Voprosy prakticheskoi kolposkopii. Genitalnye infektsii. 2023;(1):24-30 (in Russian)]. doi: 10.46393/27826392_2023_1_24
- Ермакова Е.И., Сметник А.А. Опыт клинического применения негормонального вагинального крема для лечения генитоуринарного менопаузального синдрома/вульвовагинальной атрофии у пациенток с эстрогензависимыми онкологическими заболеваниями в анамнезе. Акушерство и гинекология. 2023;8:175-84 [Ermakova EI, Smetnik AA. Opyt klinicheskogo primeneniia negormonalnogo vaginalnogo krema dlia lecheniia genitourinarnogo menopauzalnogo sindroma/vulvovaginalnoi atrofii u patsientok s estrogenzavisimymi onkologicheskimi zabolevaniiami v anamneze. Akusherstvo i Ginekologiia. 2023;8:175-84 (in Russian)]. DOI:10.18565/ aig.2023.192
- Доброхотова Ю.Э., Ильина И.Ю., Венедиктова М.Г., и др. Локальная негормональная терапия больных с генитоуринарным менопаузальным синдромом. Российский вестник акушера-гинеколога. 2018;18(3):88-94 [Dobrokhotova YuE, Ilyina IYu, Venediktova MG. Local nonhormonal therapy in patients with genitourinary menopausal syndrome. Russ Bull Obstet Gynecol. 2018;18(3):88-94 (in Russian)]. doi: 10.17116/rosakush201818388-94
Supplementary files

